NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Clinical trials for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bladder cancer drug TARA-002 faces chemotherapy in major trial
Disease control Recruiting nowThis phase 3 trial tests whether a new drug, TARA-002, works better than standard chemotherapy for a type of early-stage bladder cancer. About 284 adults who have not received BCG therapy will be randomly assigned to receive either TARA-002 or chemotherapy directly into the bladd…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE3 • Sponsor: Protara Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New Gene-Based bladder cancer treatment shows promise in early trial
Disease control Recruiting nowThis study tests a new drug called EG-70 (detalimogene) for a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). The drug is given directly into the bladder through a catheter. The trial includes patients whose cancer did not respond to standard BCG therapy…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE1, PHASE2 • Sponsor: enGene, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New gene therapy combo could offer bladder cancer patients an alternative to surgery
Disease control Recruiting nowThis phase 3 trial is testing a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or combined with chemotherapy or immunotherapy. It is for people with a type of bladder cancer that has not responded to standard BCG therapy. The study aim…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for bladder cancer patients who failed standard treatment
Disease control Recruiting nowThis study tests a new drug called Ruvidar, given directly into the bladder, for people with a type of bladder cancer that did not respond to or could not tolerate standard BCG therapy. About 90 adults will receive up to three treatment sessions. The main goal is to see if the dr…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: Theralase® Technologies Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC